ストックスクリーナーアプリを入手
9.17
7.25%
0.62
アフターアワーズ：
9.00
-0.17
-1.85%
前日終値:
$8.55
開ける：
$8.66
24時間の取引高:
1.54M
Relative Volume:
1.25
時価総額：
$599.03M
収益：
$141.31M
当期純損益:
$-297.87M
株価収益率:
-1.7003
EPS:
-5.3933
ネットキャッシュフロー:
$-168.20M
1週間 パフォーマンス:
+14.62%
1か月 パフォーマンス:
+24.42%
6か月 パフォーマンス:
+11.29%
1年 パフォーマンス:
+6.88%
1日の値動き範囲:
$8.66
$9.21
1週間の範囲:
$7.76
$9.21
52週間の値動き範囲:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
名前
Ginkgo Bioworks Holdings Inc
セクター
電話
(877) 442-5362
住所
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.17 | 599.03M | 141.31M | -297.87M | -168.20M | -5.3933 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-15 | ダウングレード | BTIG Research | Neutral → Sell |
| 2024-05-10 | ダウングレード | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-06-02 | ダウングレード | Goldman | Neutral → Sell |
| 2023-05-11 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | 開始されました | Berenberg | Buy |
| 2022-10-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-02-23 | 開始されました | Goldman | Neutral |
| 2022-02-01 | 開始されました | BofA Securities | Neutral |
| 2022-01-28 | 開始されました | BofA Securities | Buy |
| 2022-01-07 | 開始されました | BTIG Research | Buy |
| 2021-11-29 | 開始されました | Jefferies | Buy |
| 2021-10-13 | 開始されました | Raymond James | Outperform |
| 2021-10-12 | 開始されました | William Blair | Outperform |
| 2021-09-20 | 開始されました | HSBC Securities | Buy |
すべてを表示
Ginkgo Bioworks Holdings Inc (DNA) 最新ニュース
DNA Technical Analysis & Stock Price Forecast - Intellectia AI
Ginkgo Bioworks Holdings Inc (DNA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Institutional Confidence - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ginkgo Bioworks Holdings Inc - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ginkgo Bioworks Holdings Inc (DNA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant - Stock Titan
Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs - Stock Titan
Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs - Stock Titan
Ginkgo Bioworks Holdings, Inc. Files Form 8-K With SEC for June 2026 – Key Submission Details and Company Information 17 – Minichart - Minichart
Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay - Stock Titan
Ginkgo Bioworks (DNA) Short Interest & Short Float | Updated Jun 2026 $DNA - MarketBeat
Austin Che (DNA) files Form 144 showing sales totaling tens of thousands of Class A shares - Stock Titan
Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones - Stock Traders Daily
Ginkgo Bioworks Holdings, Inc. - MLQ.ai
Top Ginkgo Bioworks (DNA) Competitors 2026 - MarketBeat
Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
Technical Reactions to DNA Trends in Macro Strategies - Stock Traders Daily
Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale - Stock Titan
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - Investing News Network
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - marketscreener.com
Ginkgo Bioworks, Tangible Scientific, And Inductive Bio Launch ADME-One High-Throughput ADME Platform - marketscreener.com
New AI lab service aims for fewer dead ends in drug discovery - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - MSN
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Steve Coen (DNA) files Form 144 to sell 307 Class A shares - Stock Titan
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? - Yahoo Finance
DNA Technical Analysis | Trend, Signals & Chart Patterns | GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) - ChartMill
Trading the Move, Not the Narrative: (DNA) Edition - Stock Traders Daily
Ginkgo Bioworks Announces Presentations at the Upcoming American - GuruFocus
Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person - Stock Titan
Ginkgo Bioworks Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:DNA) 2026-05-13 - Seeking Alpha
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M - MSN
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks - MSN
Ginkgo Bioworks: Another Lost Year (NYSE:DNA) - Seeking Alpha
Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA) - Stock Titan
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - 富途牛牛
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
The $59B Quiet Shift Reshaping How Patients Access Care - Benzinga
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut - Yahoo Finance
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
TradingKey - TradingKey
Number of shareholders of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Ginkgo Bioworks Q1 Earnings Call Highlights - Barchart.com
Ginkgo Bioworks Earnings Call: Cash Rich, Revenue Pinched - TipRanks
DNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ginkgo Bioworks Holdings Inc (DNA) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):